Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

A Pilot Study to Investigate Platelet Reactivity in Patients With Elevated Lipoprotein(a) and Its Response to Antiplatelet Therapy (Lp(a)-PLAT)

17. juli 2026 opdateret af: François MACH

A Pilot Study to Investigate Platelet Reactivity in Patients With Elevated Lipoprotein(a) and Its Response to Antiplatelet Therapy Randomised, Open-Label, Mechanistic Pilot Study With A Crossover Design

The Lp(a)-PLAT Study is designed to close a critical evidence gap in cardiovascular prevention for the roughly 20% of the population who carry genetically determined elevations in lipoprotein(a) - a recognised pro-thrombotic and pro-atherosclerotic risk factor. Its objective is to delineate the pro-thrombotic platelet phenotype driven by high Lp(a) levels and to evaluate, through pharmacodynamic comparison, how two standard-of-care antiplatelet strategies - clopidogrel, a P2Y12 ADP-receptor inhibitor, and aspirin, a COX-1 inhibitor - differ in their capacity to attenuate this platelet hyperreactivity.

This study will provide the first head-to-head mechanistic comparison of clopidogrel versus aspirin on platelet reactivity in patients with elevated plasma levels of Lp(a).

Studieoversigt

Status

Ikke rekrutterer endnu

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

60

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

  • Schweiz
      • Geneva, Schweiz, 1205
        • Hôpitaux universitaires de Genève
        • Kontakt:
        • Ledende efterforsker:
          • François Mach, Prof

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

  • Voksen
  • Ældre voksen

Tager imod sunde frivillige

Ja

Beskrivelse

Inclusion Criteria:

  • Age ≥ 18 years at the time of informed consent.
  • Ability to provide written informed consent in accordance with Swiss Human Research Act (HRA) and ICH-GCP.
  • Documented plasma lipoprotein(a) [Lp(a)] concentration:

High Lp(a) cohort: ≥ 125 nmol/L (approximately ≥ 75th percentile) Low Lp(a) comparator cohort (if applicable): < 25-30 nmol/L

  • Clinically stable at the time of inclusion, with no acute cardiovascular event within the previous 3 months.
  • Willingness and ability to comply with all study procedures, including blood sampling and study medication intake.
  • For women of childbearing potential: willingness to use adequate contraception during the study period (if applicable according to local ethics requirements).

Exclusion Criteria:

  • Cardiovascular and bleeding-related conditions Active bleeding or known bleeding disorder. History of hemorrhagic stroke or intracranial hemorrhage. High risk of bleeding as judged by the investigator. Platelet count < 100 × 10⁹/L at screening. Known platelet function disorder.
  • Contraindications to study medications Known hypersensitivity or contraindication to aspirin (acetylsalicylic acid) or clopidogrel.

History of aspirin-induced asthma, severe NSAID intolerance, or anaphylactic reaction to salicylates.

Active peptic ulcer disease or clinically significant gastrointestinal bleeding within the past 6 months.

- Concomitant medications and interference with platelet function Current use of dual antiplatelet therapy (DAPT), oral anticoagulants (e.g., DOACs, vitamin K antagonists), or other potent antithrombotic agents that cannot be safely interrupted.

Use of non-steroidal anti-inflammatory drugs (NSAIDs) within 7 days prior to study entry (unless discontinued per protocol).

Use of P2Y12 inhibitors or aspirin within an insufficient washout period. - Clinical conditions Severe hepatic impairment (ALT/AST > 3× ULN) or severe renal impairment (eGFR < 30 mL/min/1.73 m²).

Active malignancy requiring systemic chemotherapy. Known hematologic disorder affecting platelet function or coagulation. Acute infection or inflammatory condition likely to affect platelet function.

- Other exclusions Pregnancy or breastfeeding. Participation in another interventional clinical trial within the last 30 days or 5 half-lives of the investigational product, whichever is longer.

Any condition that, in the opinion of the investigator, would interfere with study participation, compliance, or interpretation of results.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Forebyggelse
  • Tildeling: Randomiseret
  • Interventionel model: Crossover opgave
  • Maskning: Enkelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Aspirin → Clopidogrel Sequence
Participants receive aspirin 100 mg once daily for 14 days, followed by a 14-day washout period, then clopidogrel 75 mg once daily for 14 days. Platelet function is assessed at baseline and after each treatment period.
Medicin: Aspirin
Aspirin 100 mg administered orally once daily for 14 consecutive days during one treatment period of the randomized crossover study. Participants receive aspirin either during Period 1 or Period 2 depending on the randomized treatment sequence. A 14-day washout period separates the two treatment periods.
Medicin: Clopidogrel
Clopidogrel 75 mg administered orally once daily for 14 consecutive days during one treatment period of the randomized crossover study. Participants receive clopidogrel either during Period 1 or Period 2 depending on the randomized treatment sequence. A 14-day washout period separates the two treatment periods.
Eksperimentel: Clopidogrel → Aspirin Sequence
Participants receive clopidogrel 75 mg once daily for 14 days, followed by a 14-day washout period, then aspirin 100 mg once daily for 14 days. Platelet function is assessed at baseline and after each treatment period.
Medicin: Aspirin
Aspirin 100 mg administered orally once daily for 14 consecutive days during one treatment period of the randomized crossover study. Participants receive aspirin either during Period 1 or Period 2 depending on the randomized treatment sequence. A 14-day washout period separates the two treatment periods.
Medicin: Clopidogrel
Clopidogrel 75 mg administered orally once daily for 14 consecutive days during one treatment period of the randomized crossover study. Participants receive clopidogrel either during Period 1 or Period 2 depending on the randomized treatment sequence. A 14-day washout period separates the two treatment periods.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Change in collagen-induced platelet aggregation after aspirin versus clopidogrel treatment
Tidsramme: Baseline and Day 14 of each treatment period (up to 42 days)
Within-participant change from baseline in collagen-induced platelet aggregation measured by light transmission aggregometry (LTA) after 14 days of aspirin 100 mg once daily compared with 14 days of clopidogrel 75 mg once daily in the randomized crossover design.
Baseline and Day 14 of each treatment period (up to 42 days)
Change in soluble platelet activation biomarkers after aspirin versus clopidogrel treatment
Tidsramme: Baseline and Day 14 of each treatment period (up to 42 days)
Within-participant change from baseline in soluble platelet activation biomarkers (including soluble P-selectin/CD62P, soluble CD40 ligand [sCD40L], platelet factor 4 [PF4], and related biomarkers) following 14 days of aspirin 100 mg once daily compared with 14 days of clopidogrel 75 mg once daily.
Baseline and Day 14 of each treatment period (up to 42 days)

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Agonist-specific platelet aggregation
Tidsramme: Baseline and Day 14 of each treatment period (up to 42 days)
Change from baseline in platelet aggregation measured by light transmission aggregometry following stimulation with arachidonic acid, ADP, and TRAP-6 after each treatment period.
Baseline and Day 14 of each treatment period (up to 42 days)
Platelet surface activation markers
Tidsramme: Baseline and Day 14 of each treatment period (up to 42 days)
Change from baseline in platelet surface expression of CD62P (P-selectin) and activated GPIIb/IIIa measured by flow cytometry following aspirin and clopidogrel treatment.
Baseline and Day 14 of each treatment period (up to 42 days)
Biochemical verification of aspirin pharmacodynamic effect
Tidsramme: Day 14 of the aspirin treatment period
Serum thromboxane B2 (TxB2) concentration measured to verify cyclooxygenase-1 inhibition during aspirin treatment.
Day 14 of the aspirin treatment period
Biochemical verification of clopidogrel pharmacodynamic effect
Tidsramme: Day 14 of the clopidogrel treatment period
Vasodilator-stimulated phosphoprotein (VASP) platelet reactivity index (PRI) measured to verify P2Y12 receptor inhibition during clopidogrel treatment.
Day 14 of the clopidogrel treatment period
Association between plasma lipoprotein(a) concentration and platelet function
Tidsramme: Baseline and Day 14 of each treatment period (up to 42 days)
Correlation between plasma lipoprotein(a) concentration and platelet function parameters measured by light transmission aggregometry, flow cytometry, and soluble biomarkers.
Baseline and Day 14 of each treatment period (up to 42 days)
Baseline comparison of platelet reactivity between participants with high and low lipoprotein(a)
Tidsramme: Baseline (Day 0)
Comparison of baseline platelet function parameters between participants with elevated lipoprotein(a) (>125 nmol/L) and matched participants with low lipoprotein(a) (<25 nmol/L).
Baseline (Day 0)
Plasma proteomic profile associated with lipoprotein(a) and antiplatelet therapy (Exploratory)
Tidsramme: Baseline and Day 14 of each treatment period (up to 42 days)
Exploratory analysis of plasma proteins measured using the Olink® proximity extension assay platform to identify proteins associated with elevated lipoprotein(a), platelet reactivity, and treatment with aspirin or clopidogrel.
Baseline and Day 14 of each treatment period (up to 42 days)

Andre resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Identification of candidate biomarkers associated with lipoprotein(a)-related platelet hyperreactivity
Tidsramme: Baseline and Day 14 of each treatment period (up to 42 days)
Exploratory identification of circulating protein biomarkers associated with platelet hyperreactivity and pharmacodynamic response to aspirin and clopidogrel using Olink® proteomic analysis. Results are hypothesis-generating only.
Baseline and Day 14 of each treatment period (up to 42 days)

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

François MACH

Samarbejdspartnere

University Hospital, Geneva

Efterforskere

  • Ledende efterforsker: François Mach, Prof, HUG

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

1. november 2026

Primær færdiggørelse (Anslået)

1. marts 2027

Studieafslutning (Anslået)

1. november 2027

Datoer for studieregistrering

Først indsendt

17. juli 2026

Først indsendt, der opfyldte QC-kriterier

17. juli 2026

Først opslået (Faktiske)

22. juli 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

22. juli 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

17. juli 2026

Sidst verificeret

1. juli 2026

Mere information

Begreber relateret til denne undersøgelse

Nøgleord

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • 2026-01415

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

IPD-planbeskrivelse

Individual participant data collected during the Lp(a)-PLAT study, including clinical data, laboratory results, and platelet function measurements, will not be shared in public data repositories.

Given the mechanistic nature of the study and the small sample size, there is a potential risk of indirect re-identification of participants even after standard anonymisation procedures. Therefore, raw participant-level datasets will remain under controlled access within the Sponsor institution (Hôpitaux Universitaires de Genève, HUG).

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

produkt fremstillet i og eksporteret fra U.S.A.

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med Kardiovaskulær forebyggelse

Kliniske forsøg med Aspirin

Søg i lignende forsøg

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

CROs by country

CROs in Suriname

Betingelser

Sjældne sygdomme

Narkotikainterventioner

Kosttilskud

Sponsor / samarbejdspartnere

Placeringer

Abonner